Dr. Jacqueline Lui, President of Eagle IP Group, gave a talk at The First Intellectual Property Communication Salon and the opening ceremony fo the Greater China Intellectual Property Attorneys Association (GCIPAA).

Details of the event and registration can be found at this link

Our Past Events

Recommended Insights

CHINA: New Patent Examination Guidelines Now Available for Public Comment

4 August 2021
Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

10 March 2025
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]

AI is magical but NOT magic! Be specific in your AI patents!

9 January 2025
What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

29 April 2021
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
Top crossarrow-right